Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Envoy Medical, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, Envoy Medical reported a net loss of $14.3 million, an improvement from the $17.2 million loss in the prior year period. The company strengthened its balance sheet through a February 2026 offering, increasing cash to $14.6 million and significantly reducing its stockholders' deficit.
Envoy Medical reported third quarter 2026 financial results and provided a clinical update on its Acclaim fully implanted cochlear implant. The company reached a six-month follow-up milestone for its full pivotal trial cohort and submitted the second module of its Modular PMA application to the FDA.
“We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as we approach an extremely exciting 2027. Not only did we report encouraging 12-month data from the first 10 participants in our trial, but we also surpassed the three-month follow-up mark for the full cohort. Since quarter end, we have now surpassed the six-month follow-up milestone. We remain on track for all participants to complete their 12-month visits by early in the second quarter of 2027. Each milestone brings us closer to offering cochlear implant candidates a fully implanted option they have wanted for decades.”
Brent Lucas, Chief Executive Officer of Envoy Medical
Envoy Medical implemented a 1-for-10 reverse stock split of its Class A common stock, effective October 26, 2026. The split is intended to regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. Every 10 shares of outstanding common stock were automatically combined into one share, with fractional shares settled in cash.
Envoy Medical stockholders approved an amendment to the certificate of incorporation to authorize a reverse stock split of Class A Common Stock at a ratio between 1-for-5 and 1-for-25. The Board of Directors has the discretion to effect the split at any time on or before December 31, 2026.
Envoy Medical entered into a Dismissal Agreement with Atlas Merchant Capital SPAC Fund I LP to resolve litigation in the Delaware Court of Chancery. The litigation concerned allegations that Atlas was not permitted to redeem its shares during the company's September 2023 business combination. All claims will be dismissed with prejudice with no payment required from Envoy Medical or other defendants.